Translink Corporate Finance has advised Cortex Technology, a Danish company and one of the global leaders in medical devices for cryotherapy and dermatology on their sale to Vækst Invest. Cortex Technology’s products are distributed worldwide – mainly through local suppliers.
Cortex Technology has profits of more than 1 mill € with strong growth, which is expected to continue through the introduction of several new products. The main product lines are:
- Cryo therapy products, typically sold to the primary care sector
- Dermatology products for various types of skin analysis, sold to professional customers such as cosmetics producers, research organizations and cosmetologists
The current growth is supported by a strong product road map, and the global sales focus will be intensified by the sale of 60% of the shares to Vækst Invest – a Danish PE fund focusing on growth companies within the SME segment in Denmark.
The transaction was closed on January 25th, 2021.
Steffen Vogel, former owner of Cortex Technology:
“Based on our earlier contact and recommendations we chose Translink Corporate Finance as our M&A adviser, being responsible for the transaction process and finding the best future partner for us – a partner and co-shareholder who could help us to realize the significant growth potential we see in our industry. In the middle of the operation the corona outbreak occurred – and controlling the process during this phase was not easy.
Translink Corporate Finance presented a significant list with very relevant international candidates, and a Danish buyer ended up making the best offer. The process was guided and controlled in a very professional way by Henrik and Claus.”
Claus Melgaard, Partner
Henrik Schrøder, Partner
“Even though it was a smaller transaction and the buyer finally was a Danish PE-fund, Translink demonstrated its strength in running a competitive process identifying several relevant potential buyers from around the globe.” says Henrik.
Contact our Team Members having supported this transaction